Navigation Links
InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
Date:5/16/2011

on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union in adults for the treatment of mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to commercial launch preparations, anticipated timing of commercial launch and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the foll
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
2. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
3. InterMune to Release First Quarter Financial Results on April 28
4. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
5. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
6. InterMune to Release Third Quarter Financial Results on October 28
7. InterMune Sells Danoprevir Rights to Roche for $175 Million
8. InterMune to Present at 2010 Citi Health Care Conference
9. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
10. InterMune to Release First Quarter Financial Results on April 29
11. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 28, 2015 ... Markets ( http://www.researchandmarkets.com/research/8h5hs2/animal ) has announced the ... "Animal Biotechnology - Technologies, Markets and ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This report describes and ... in veterinary medicine and pharmaceuticals as ...
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
(Date:5/28/2015)... 2015  PDS Biotechnology Corp. announces preliminary data ... HPV-16, has generated strong T-cell responses in pre-cervical ... is treated by surgical removal of lesions however, ... alternative. Results show that it primes and activates ... and kill precancerous and cancerous cells that display ...
(Date:5/28/2015)... The Fertility Centers of New England ... Vitiello has taken on a new and expanded role ... provide guidance, leadership, oversight and quality assurance for the ... among our team of experienced reproductive endocrinologists,” said Fertility ... Hill, M.D. “Her expertise and compassionate, individualized care have ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... The 2011 Frost & Sullivan Europe New Product Innovation ... (Novelda) for its state-of-the-art, high precision Novelda Impulse Radar ... Impulse Radar transceiver is a cutting-edge radar transceiver that ... to unique penetration capabilities," remarks Frost & Sullivan Research ...
... Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ), ... commercialization of medically important pharmaceutical products for the treatment ... conference call will be held on Monday, May 2, ... the first quarter ended March 31, 2011 and a ...
... KALAMAZOO, Mich., April 28, 2011 Vestaron Corporation, a ... insecticide products, announced today that John Sorenson, Ph.D., will ... Board of Directors thanks John McIntyre for his years ... for agriculture. "John,s scientific leadership has been ...
Cached Biology Technology:Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 2Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 3Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 4Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results 2Vestaron Corporation Announces New Leadership 2Vestaron Corporation Announces New Leadership 3
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... the protective membranes of cells, researchers have demonstrated a ... DNA directly into living cells. Carbon nanoparticles ... blasts, which open holes in cell membranes just long ... fluid. By adjusting laser exposure, the researchers administered ...
... This release is available in Spanish . ... tool for deciphering the genetics of a native prairie grass ... The genetic map of switchgrass, published by Christian Tobias, a ... Albany, Calif., and his colleagues, is expected to speed up ...
... 27, 2010 Ben-Gurion University of the Negev (BGU) researchers ... at age 17 can still predict hypertension at early adulthood ... likely to develop high blood pressure in early adulthood than ... Hypertension: Journal of the American Heart Association , the research ...
Cached Biology News:Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 3Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 4A new tool for improving switchgrass 2Ben-Gurion University of the Negev researchers identify risks of hypertension in young adults 2
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
... Human Pathogenic Viruses The ... (NCPV) preserves well characterised, authenticated ... secure facility, and NCPV is ... or nucleic acids derived from ...
... 5 Fluorescein 6-Fam, Hex, ... 3 Fluorescein Tamra Black Hole ... 6-Fam, Hex, Tet Tamra, Joe ... Health Research Institute, New York Double labelled ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: